Dendreon to offer end-to-end cell therapy manufacturing

By The Science Advisory Board staff writers

June 16, 2021 -- California-based Dendreon Pharmaceuticals announced that it will offer end-to-end manufacturing for complex cell therapies.

The company is one of only four firms that manufacture cell therapies for commercial use in the U.S. In early 2021, Dendreon started to dedicate capacity for later-stage partner programs within its current infrastructure.

Copyright © 2021

Laboratory Products Association Annual Meeting
October 1-4
Scottsdale, Arizona United States
Cell & Gene Meeting on the Mesa
October 11-13
Carlsbad, California United States
IDWeek 2022
October 19-23
District of Columbia United States
American Society of Human Genetics Annual Meeting
October 25-29
Los Angeles, California United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter